ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1680

Diagnostic Value of the Assessment of Spondyloarthropathy International Society (ASAS) Criteria for Children with Enthesitis Related Arthritis (ERA): A Single Center Study of 124 Patients

Mehul Jariwala1, Manjari Agarwal1 and Sujata Sawhney2, 1Institute of Child Health, Sir Ganga Ram Hospital, New Delhi, India, 2Paediatric rheumatology, Sir Ganga Ram Hospital, New Delhi, India

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Assessment, Enthesitis, juvenile idiopathic arthritis (JIA) and spondylarthropathy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Pediatric Rheumatology: Clinical and Therapeutic Disease II: Juvenile Idiopathic Arthritis II

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Enthesitis Related Arthritis (ERA) is a common subtype (36%) of Juvenile Idiopathic Arthritis (JIA) seen in India 1. These criteria do not distinguish between axial and peripheral arthritis. The new ASAS criteria 2,3do, and have to date been applied only to the adult population. This distinction is important from both the diagnostic and therapeutic viewpoint. Therefore, we applied the ASAS criteria to our ERA patients. This is the first study of its kind.

  1. Agarwal et al. 110 patients with Enthesitis Related Arthritis: a demographic and clinical study from a tertiary level pediatric rheumatology centre in India.THU0321; EULAR 2012.
  2. Rudwaleit M, et al. The ASAS classification criteria for peripheral SpA. Ann Rheum Dis; 2011; 70(1):25-31.
  3. van der Heijde Dse et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in axial SpA. Ann Rheum Dis.2011;70(6):905-8.

Methods:

Data on JIA patients at our centre is collected on detailed proformas at onset and thereafter quarterly. All ERA patients seen over a three year period from May 2009-12 were included. ASAS axial and peripheral spondyloarthritis (SpA) criteria were retrospectively applied to this cohort, taking all features within 6 months of disease onset.

Results:

ERA:  124 children were identified, 102 were boys. Median age of onset was 10.9 years; median delay to diagnosis 5months. ERA features: 64 had arthritis and enthesitis; 60 had Enthesitis or Arthritis with  ≥ 2 of the following: SI tenderness and/or inflammatory spinal pain 28%, HLA-B27 97.6%, Family history of medically confirmed HLA-B27-associated disease 9.7%, Anterior uveitis 16.1%, Onset of arthritis in a boy after 6 yr of age 83.8%.

ASAS criteria: All 124 ERA patients could be classified per the ASAS criteria. The prevalence of each item is in Table1. No patient in this cohort had isolated inflammatory back pain (IBP) without any other feature of SpA. Thirty five children had axial and 89 peripheral SpA. Only 1 patient had imaging evidence of sacroiliitis with no back pain. All children in this study with axial complaints had IBP.

 Additional data:97.6% patients were HLAB27 positive, 19.4% had hip disease and 28.2% of SI joint MRIs were positive. A further 12 patients developed new onset inflammatory back pain over the observation period of 3 years.

 Table 1

SpA features

Axial SpA

Axial SpA

Peripheral SpA

Peripheral SpA

 

Low back pain >3months + Sacroiliac imaging + ≥1 SpA feature

n=29

Low Back Pain + HLAB27 + ≥ 2 SpA features

n=6

Arthritis or Enthesitis or Dactylitis + ≥1 SpA feature

n=88

 

Arthritis or Enthesitis or Dactylitis + ≥2 SpA feature

n=1

IBP

29 (100%)

6 (100%)

NA

NA

Arthritis

25 (86.2%)

5 (83.3%)

88 (100%)

1 (100%)

Enthesitis (heel)

9 (31%)

0 (0%)

NA

NA

Uveitis

3 (10.3%)

1 (16.67%)

16 (18.18%)

NA

Dactylitis

0 (0%)

0 (0%)

3 (3.4%)

0 (0%)

Psoriasis

0 (0%)

0 (0%)

0 (0%)

NA

Crohn’s/Ulcerative Colitis

1 (3.4%)

1 ( 16.67%)

1 (1.13%)

NA

Good response to NSAIDs

23 (79.3%)

5 (83.33%)

NA

NA

Family h/o SpA

7 (24%)

0 (0%)

NA

0 (0%)

HLAB27

29 (100%)

6 (100%)

87 (98.86%)

NA

Elevated ESR*

20 ( 69%)

4 (100%)

NA

NA

Preceding infection

NA

NA

6 (6.81%)

NA

SI imaging

NA

NA

5 (5.68%)

NA

Enthesitis (any)

NA

NA

46 (52.27%)

0 (0%)

IBP ever

NA

NA

NA

0 (0%)

*CRP replaced by ESR

Conclusion:

The ASAS axial and peripheral SpA criteria can be applied to all children with ERA and have a sensitivity of 100%, peripheral SpA is 2.5 times as common as the axial SpA. Thus in the pediatric population the entry criteria should be peripheral and not axial disease. This has important implications for deciding therapeutic pathways in children with axial or peripheral disease and gives an oppurtunity to childen with SpA to be recruited into clinical trials  with same diagnostic criteria as for adults. We plan to expand the application of these criteria to the undifferentiated and psoriatic arthritis categories of JIA as well.


Disclosure:

M. Jariwala,
None;

M. Agarwal,
None;

S. Sawhney,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/diagnostic-value-of-the-assessment-of-spondyloarthropathy-international-society-asas-criteria-for-children-with-enthesitis-related-arthritis-era-a-single-center-study-of-124-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology